Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation.

Doan VP, Yeh JC, Gulbis AM, Aitken SL, Ariza-Heredia E, Ahmed S.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1637-1641. doi: 10.1016/j.bbmt.2019.04.013. Epub 2019 Apr 17.

PMID:
31002991
2.

Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses.

Kawedia JD, Kalariya N, Gulbis AM, Andersson BS, Myers AL.

Clin J Oncol Nurs. 2019 Apr 1;23(2):191-196. doi: 10.1188/19.CJON.191-196.

PMID:
30880803
3.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
4.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

5.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13. No abstract available.

6.

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM.

Bone Marrow Transplant. 2018 Mar;53(3):315-325. doi: 10.1038/s41409-017-0034-z. Epub 2017 Dec 21.

PMID:
29269797
7.

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.

Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, Gulbis AM, Sharma P.

Clin Cancer Res. 2018 Mar 1;24(5):1011-1018. doi: 10.1158/1078-0432.CCR-17-2777. Epub 2017 Dec 15.

8.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.

9.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL Jr, Khouri IF.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1405-1410. doi: 10.1016/j.bbmt.2017.04.027. Epub 2017 May 8.

10.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.

Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM.

Bone Marrow Transplant. 2017 Jan;52(1):28-33. doi: 10.1038/bmt.2016.204. Epub 2016 Sep 5.

11.

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.

El-Haddad D, El Chaer F, Vanichanan J, Shah DP, Ariza-Heredia EJ, Mulanovich VE, Gulbis AM, Shpall EJ, Chemaly RF.

Antiviral Res. 2016 Oct;134:58-62. doi: 10.1016/j.antiviral.2016.08.024. Epub 2016 Aug 28.

PMID:
27582067
12.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Dec;26(12):2507-8. doi: 10.1093/annonc/mdv479. Epub 2015 Oct 20. No abstract available.

13.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

14.

Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.

Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK, Champlin RE, Chemaly RF.

Transpl Infect Dis. 2014 Dec;16(6):878-86. doi: 10.1111/tid.12312. Epub 2014 Nov 18.

PMID:
25405922
15.

Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients.

Merten JA, Shapiro JF, Gulbis AM, Rao KV, Bubalo J, Lanum S, Engemann AM, Shayani S, Williams C, Leather H, Walsh-Chocolaad T.

Biol Blood Marrow Transplant. 2013 Apr;19(4):509-18. doi: 10.1016/j.bbmt.2012.12.022. Epub 2013 Feb 15. Review.

16.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA.

Blood. 2012 Jun 28;119(26):6373-8. doi: 10.1182/blood-2012-03-417808. Epub 2012 May 14.

17.

Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients.

Howell JE, Gulbis AM, Champlin RE, Qazilbash MH.

Am J Hematol. 2012 Feb;87(2):172-4. doi: 10.1002/ajh.22229. Epub 2011 Nov 12.

18.

Busulfan and metronidazole: an often forgotten but significant drug interaction.

Gulbis AM, Culotta KS, Jones RB, Andersson BS.

Ann Pharmacother. 2011 Jul;45(7-8):e39. doi: 10.1345/aph.1Q087. Epub 2011 Jul 5.

PMID:
21730282

Supplemental Content

Loading ...
Support Center